BioProcess International

The CEO of a pharmaceutical cost-reduction company explains why medicine prices continue to rise.

Refusing to be content with the standard format of an antibody, small-molecule cytotoxin, and chemical linker, drug developers are extending the logic of ADCs to provide selective delivery of novel payloads.

A professor from Yonsei University tells us how South Korea is preparing to meet the needs of the fast-growing biotech industry through education and training.

A startup biotech company out of King’s College London is using hypoxia to target solid tumors.

Our discussion with experts from Lithuania concludes as we explore the US−Lithuania corridor, free economic zones, and the country’s role in shaping the future of biotech.

The pharma company’s latest peptide is so effective, it’s raising eyebrows among medical professionals.

As industry shifts from batch to continuous manufacturing, process engineers and data scientists increasingly must integrate process design, digital infrastructure, automation, and real-time control into adaptive, flow-based operations. Thus, engineers are becoming critical to delivering resilient, efficient, and compliant continuous-manufacturing systems.

Aragen manufactures first commercial GMP batches of Daretabart for Renaissance Pharma, a mAb targeting high-risk neuroblastoma with FDA Fast Track status.

The Princeton based biotech firm will make stem cell therapy implants for a federally funded clinical trial.

The partnership will focus on automating T-cell receptor therapies for blood cancers.